501
|
Gal S, Fridkin M, Amit T, Zheng H, Youdim MBH. M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease. JOURNAL OF NEURAL TRANSMISSION. SUPPLEMENTUM 2006:447-56. [PMID: 17017567 DOI: 10.1007/978-3-211-45295-0_68] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Abstract
Iron and monoamine oxidase activity are increased in brain of Parkinson's disease (PD). They are associated with autoxidation and oxidative deamination of dopamine by MAO resulting in the generation of reactive oxygen species and the onset of oxidative stress to induce neurodegeneration. Iron chelators (desferal, Vk-28 and clioquinol) but not copper chelators have been shown to be neuroprotective in the 6-hydroxydoapmine and MPTP models of Parkinson's disease (PD), as are monoamine oxidase B inhibitors such as selegiline and rasagiline. These findings prompted the development of multifunctional anti PD drugs possessing iron chelating phamacophore of VK-28 and the propargylamine MAO inhibitory activity of rasagiline. M30 is a potent iron chelator, radical scavenger and brain selective irreversible MAO-A and B inhibitor, with little inhibition of peripheral MAO. It has neuroprotective activity in in vitro and in vivo models of PD and unlike selective MAO-B inhibitors it increases brain dopamine, serotonin and noradrenaline. These findings indicate beside its anti PD action, it may also possess antidepressant activity, similar to selective MAO-A and nonselective MAO inhibitors. These properties make it an ideal anti PD drug for which it is being developed.
Collapse
|
502
|
Mannella N, Yang WL, Zhou XJ, Zheng H, Mitchell JF, Zaanen J, Devereaux TP, Nagaosa N, Hussain Z, Shen ZX. Nodal quasiparticle in pseudogapped colossal magnetoresistive manganites. Nature 2005; 438:474-8. [PMID: 16306987 DOI: 10.1038/nature04273] [Citation(s) in RCA: 210] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2005] [Accepted: 09/19/2005] [Indexed: 11/09/2022]
Abstract
A characteristic feature of the copper oxide high-temperature superconductors is the dichotomy between the electronic excitations along the nodal (diagonal) and antinodal (parallel to the Cu-O bonds) directions in momentum space, generally assumed to be linked to the 'd-wave' symmetry of the superconducting state. Angle-resolved photoemission measurements in the superconducting state have revealed a quasiparticle spectrum with a d-wave gap structure that exhibits a maximum along the antinodal direction and vanishes along the nodal direction. Subsequent measurements have shown that, at low doping levels, this gap structure persists even in the high-temperature metallic state, although the nodal points of the superconducting state spread out in finite 'Fermi arcs'. This is the so-called pseudogap phase, and it has been assumed that it is closely linked to the superconducting state, either by assigning it to fluctuating superconductivity or by invoking orders which are natural competitors of d-wave superconductors. Here we report experimental evidence that a very similar pseudogap state with a nodal-antinodal dichotomous character exists in a system that is markedly different from a superconductor: the ferromagnetic metallic groundstate of the colossal magnetoresistive bilayer manganite La1.2Sr1.8Mn2O7. Our findings therefore cast doubt on the assumption that the pseudogap state in the copper oxides and the nodal-antinodal dichotomy are hallmarks of the superconductivity state.
Collapse
|
503
|
Zheng H, Gal S, Weiner LM, Bar-Am O, Warshawsky A, Fridkin M, Youdim MBH. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J Neurochem 2005; 95:68-78. [PMID: 16181413 DOI: 10.1111/j.1471-4159.2005.03340.x] [Citation(s) in RCA: 163] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Iron-dependent oxidative stress, elevated levels of iron and of monoamine oxidase (MAO)-B activity, and depletion of antioxidants in the brain may be major pathogenic factors in Parkinson's disease, Alzheimer's disease and related neurodegenerative diseases. Accordingly, iron chelators, antioxidants and MAO-B inhibitors have shown efficacy in a variety of cellular and animal models of CNS injury. In searching for novel antioxidant iron chelators with potential MAO-B inhibitory activity, a series of new iron chelators has been designed, synthesized and investigated. In this study, the novel chelators were further examined for their activity as antioxidants, MAO-B inhibitors and neuroprotective agents in vitro. Three of the selected chelators (M30, HLA20 and M32) were the most effective in inhibiting iron-dependent lipid peroxidation in rat brain homogenates with IC50 values (12-16 microM), which is comparable with that of desferal, a prototype iron chelator that is not has orally active. Their antioxidant activities were further confirmed using electron paramagnetic resonance spectroscopy. In PC12 cell culture, the three novel chelators at 0.1 microM were able to attenuate cell death induced by serum deprivation and by 6-hydroxydopamine. M30 possessing propargyl, the MAO inhibitory moiety of the anti-Parkinson drug rasagiline, displayed greater neuroprotective potency than that of rasagiline. In addition, in vitro, M30 was a highly potent non-selective MAO-A and MAO-B inhibitor (IC50 < 0.1 microM). However, HLA20 was more selective for MAO-B but had poor MAO inhibition, with an IC50 value of 64.2 microM. The data suggest that M30 and HLA20 might serve as leads in developing drugs with multifunctional activities for the treatment of various neurodegenerative disorders.
Collapse
|
504
|
Gal S, Zheng H, Fridkin M, Youdim MBH. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J Neurochem 2005; 95:79-88. [PMID: 16181414 DOI: 10.1111/j.1471-4159.2005.03341.x] [Citation(s) in RCA: 154] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Several multifunctional iron chelators have been synthesized from hydroxyquinoline pharmacophore of the iron chelator, VK-28, possessing the monoamine oxidase (MAO) and neuroprotective N-propargylamine moiety. They have iron chelating potency similar to desferal. M30 is a potent irreversible rat brain mitochondrial MAO-A and -B inhibitor in vitro (IC50, MAO-A, 0.037 +/- 0.02; MAO-B, 0.057 +/- 0.01). Acute (1-5 mg/kg) and chronic [5-10 mg/kg intraperitoneally (i.p.) or orally (p.o.) once daily for 14 days]in vivo studies have shown M30 to be a potent brain selective (striatum, hippocampus and cerebellum) MAO-A and -B inhibitor. It has little effects on the enzyme activities of the liver and small intestine. Its N-desmethylated derivative, M30A is significantly less active. Acute and chronic treatment with M30 results in increased levels of dopamine (DA), serotonin(5-HT), noradrenaline (NA) and decreases in DOPAC (dihydroxyphenylacetic acid), HVA (homovanillic acid) and 5-HIAA (5-hydroxyindole acetic acid) as determined in striatum and hypothalamus. In the mouse MPTP (N-methy-4-phenyl-1,2,3,6-tetrahydropyridine) model of Parkinson's disease (PD) it attenuates the DA depleting action of the neurotoxin and increases striatal levels of DA, 5-HT and NA, while decreasing their metabolites. As DA is equally well metabolized by MAO-A and -B, it is expected that M30 would have a greater DA neurotransmission potentiation in PD than selective MAO-B inhibitors, for which it is being developed, as MAO-B inhibitors do not alter brain dopamine.
Collapse
|
505
|
Zheng H, Youdim MBH, Weiner LM, Fridkin M. Novel potential neuroprotective agents with both iron chelating and amino acid-based derivatives targeting central nervous system neurons. Biochem Pharmacol 2005; 70:1642-52. [PMID: 16226724 DOI: 10.1016/j.bcp.2005.09.003] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2005] [Revised: 09/09/2005] [Accepted: 09/12/2005] [Indexed: 11/17/2022]
Abstract
Antioxidants and iron chelating molecules are known as neuroprotective agents in animal models of neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD). In this study, we designed and synthesized a novel bifunctional molecule (M10) with radical scavenging and iron chelating ability on an amino acid carrier likely to be a substrate for system L, thus targeting the compound to the central nervous system (CNS). M10 had a moderate iron affinity in HEPES buffer (pH 7.4) with logK(3)=12.25+/-0.55 but exhibited highly inhibitory action against iron-induced lipid peroxidation, with an IC(50) value (12microM) comparable to that of desferal (DFO). EPR studies indicated that M10 was a highly potent *OH scavenger with an IC(50) of about 0.3 molar ratio of M10 to H(2)O(2). In PC12 cell culture, M10 was at least as potent as the anti-Parkinson drug rasagiline in protecting against cell death induced by serum-deprivation and by 6-hydroxydopamine (6-OHDA). These results suggest that M10 deserves further investigation as a potential agent for the treatment of neurodegenerative disorders such as AD and PD.
Collapse
|
506
|
Zheng H, Youdim MBH, Weiner LM, Fridkin M. Synthesis and evaluation of peptidic metal chelators for neuroprotection in neurodegenerative diseases. ACTA ACUST UNITED AC 2005; 66:190-203. [PMID: 16138857 DOI: 10.1111/j.1399-3011.2005.00289.x] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
A series of novel derivatives of neuropeptides with a metal-chelating moiety was synthesized and examined for various properties related to iron (Fe) chelation and neuroprotective action. All derivatives chelated Fe to form stable Fe complexes in water. Some strongly inhibited Fe-induced lipid peroxidation with an IC(50) value of about 12 microm. In PC12 cell culture, several compounds, at concentrations as low as 1 microm, attenuated serum-free stimulated cell death and improved cell survival by 20-35%. At this concentration, these analogs also protected against 6-hydroxydopamine (6-OHDA)-induced cell death, increasing cell viability by 20-30%. Electron paramagnetic resonance (EPR) studies indicated that besides being good Fe chelators, these analogs act as radical scavengers to directly scavenge hydroxyl radicals. Together, the data indicate that some of the analogs could be further developed as possible neuroprotective agents for treatment of neurodegenerative diseases such as Parkinson's, Alzheimer's, and Huntington's diseases, Friedreich's atxia, amyotrophic, and lateral sclerosis where Fe misregulation has been reported.
Collapse
|
507
|
Zheng H, Wiese K, Azuaje F. Special Section on Bioinformatics and Computational Biology. IEEE Trans Nanobioscience 2005. [DOI: 10.1109/tnb.2005.853643] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
508
|
Zavaliche F, Zheng H, Mohaddes-Ardabili L, Yang SY, Zhan Q, Shafer P, Reilly E, Chopdekar R, Jia Y, Wright P, Schlom DG, Suzuki Y, Ramesh R. Electric field-induced magnetization switching in epitaxial columnar nanostructures. NANO LETTERS 2005; 5:1793-6. [PMID: 16159226 DOI: 10.1021/nl051406i] [Citation(s) in RCA: 110] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Abstract
We present direct evidence for room-temperature magnetization reversal induced by an electric field in epitaxial ferroelectric BiFeO3-ferrimagnetic CoFe2O4 columnar nanostructures. Piezoelectric force microscopy and magnetic force microscopy were used to locally image the coupled piezoelectric-magnetic switching. Quantitative analyses give a perpendicular magnetoelectric susceptibility of approximately 1.0 x 10(-2) G cm/V. The observed effect is due to the strong elastic coupling between the two ferric constituents as the result of the three-dimensional heteroepitaxy.
Collapse
|
509
|
Wang Y, He T, Wen X, Li T, Waili TT, Zhang W, Zhou H, Zheng H, Wen H, Davaadorj N, Gambolt L, Mukhar T, Rogan MT, Craig PS. Human cystic echinococcosis in two Mongolian communities in Hobukesar (China) and Bulgan (Mongolia). Trans R Soc Trop Med Hyg 2005; 99:692-8. [PMID: 15990129 DOI: 10.1016/j.trstmh.2005.01.004] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2004] [Accepted: 01/20/2005] [Indexed: 11/29/2022] Open
Abstract
In order to investigate the prevalence of human cystic echinococcosis (CE) in traditional Mongolian communities in western Mongolia and Xinjiang (northwest China), studies were carried out between 1995 and 2000, on two ethnically identical populations in Hobukesar (China) and Bulgan (Mongolia). The prevalence of human hepatic CE in the two communities was significantly different. In Hobukesar, human CE prevalence by ultrasound was 2.7% (49/1844), while in Bulgan it was 0.2% (4/1609) (P<0.001). Dog surveys showed that coproantigen-positive rates or dog necropsy positives were similar in both communities (35.0% in Hobukesar and 35.7% in Bulgan). Comparing possible risk factors, there appeared to be some significant differences between the two communities, which might contribute to the observed difference in CE prevalence. These included: the proportion of herdsman or farmers recorded; the proportions of dog ownership and livestock ownership; and the proportion of families practising home slaughter. The presence of a Russian dog-dosing programme up to the mid-1980s may explain the lower prevalence of human CE in the Bulgan population; no similar programme operated in the China-administered Hobukesar community.
Collapse
|
510
|
Zheng H, Minor W. A dictionary approach to translate memory variables from crystallography software to mmCIF items. Acta Crystallogr A 2005. [DOI: 10.1107/s010876730509464x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
511
|
Zheng H, Weiner LM, Bar-Am O, Epsztejn S, Cabantchik ZI, Warshawsky A, Youdim MBH, Fridkin M. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg Med Chem 2005; 13:773-83. [PMID: 15653345 DOI: 10.1016/j.bmc.2004.10.037] [Citation(s) in RCA: 217] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2004] [Revised: 10/18/2004] [Accepted: 10/18/2004] [Indexed: 11/18/2022]
Abstract
Several novel antioxidant-iron chelators bearing 8-hydroxyoxyquinoline moiety were synthesized, and various properties related to their iron chelation, and neuroprotective action were investigated. All the chelators exhibited strong iron(III) chelating and high antioxidant properties. Chelator 9 (HLA20), having good permeability into K562 cells and moderate selective MAO-B inhibitory activity (IC50 110 microM), displayed the hightest protective effects against differentiated P19 cell death induced by 6-hydroxydopamine. EPR studies suggested that Chelator 9 also act as radical scavenger to directly scavenge hydroxyl radical.
Collapse
|
512
|
Zheng H, Zhao J, Wang S, Lin CM, Chen T, Jones DH, Ma C, Opella S, Xie XQ. Biosynthesis and purification of a hydrophobic peptide from transmembrane domains of G-protein-coupled CB2 receptor. ACTA ACUST UNITED AC 2005; 65:450-8. [PMID: 15813893 DOI: 10.1111/j.1399-3011.2005.00239.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
A major challenge for the structural study of the seven-transmembrane G-protein-coupled receptors is to obtain a sufficient amount of purified protein at the milligram level, which is required for either nuclear magnetic resonance (NMR) spectroscopy or X-ray crystallography. In order to develop a high-yield and cost-effective method, and also to obtain preliminary structural information for the computer modeling of the three-dimensional receptor structural model, a highly hydrophobic peptide from human cannabinoid subtype 2 receptor CB2(65-101), was chosen to develop high-yield membrane protein expression and purification methods. The peptide included the second transmembrane helix with the associated loop regions of the CB2 receptor. It was over-expressed in Escherichia coli, with a modified TrpDelta LE1413 (TrpLE) leading fusion sequence and a nine-histidine tag, and was then separated and purified from the tag in a preparative scale. An experimental protocol for the chemical cleavage of membrane protein fragment was developed using cyanogen bromide to remove the TrpLE tag from the hydrophobic fusion protein. In addition, protein uniformly labeled with isotopic 15N was obtained by expression in 15N-enriched minimum media. The developed and optimized preparation scheme of expression, cleavage, and purification provided a sufficient amount of peptide for NMR structure analysis and other biophysical studies that will be reported elsewhere. The process of fusion protein cleavage following purification was monitored by high-performance liquid chromatography (HPLC) and mass spectrometry (MS), and the final sample was validated by MS and circular dichroism experiments.
Collapse
|
513
|
Zheng H, Black ND, Harris ND. Position-sensing technologies for movement analysis in stroke rehabilitation. Med Biol Eng Comput 2005; 43:413-20. [PMID: 16255421 DOI: 10.1007/bf02344720] [Citation(s) in RCA: 64] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Research has focused on improvement of the quality of life of stroke patients. Gait detection, kinematics and kinetics analysis, home-based rehabilitation and telerehabilitation are the areas where there has been increasing research interest. The paper reviews position-sensing technologies and their application for human movement tracking and stroke rehabilitation. The review suggests that it is feasible to build a home-based telerehabilitation system for sensing and tracking the motion of stroke patients.
Collapse
|
514
|
Abazov VM, Abbott B, Abolins M, Acharya BS, Adams DL, Adams M, Adams T, Agelou M, Agram JL, Ahmed SN, Ahn SH, Alexeev GD, Alkhazov G, Alton A, Alverson G, Alves GA, Anastasoaie M, Anderson S, Andrieu B, Arnoud Y, Askew A, Asman B, Atramentov O, Autermann C, Avila C, Babukhadia L, Bacon TC, Badaud F, Baden A, Baffioni S, Baldin B, Balm PW, Banerjee S, Barberis E, Bargassa P, Baringer P, Barnes C, Barreto J, Bartlett JF, Bassler U, Bauer D, Bean A, Beauceron S, Beaudette F, Begel M, Bellavance A, Beri SB, Bernardi G, Bernhard R, Bertram I, Besançon M, Besson A, Beuselinck R, Bezzubov VA, Bhat PC, Bhatnagar V, Bhattacharjee M, Binder M, Bischoff A, Black KM, Blackler I, Blazey G, Blekman F, Blessing S, Bloch D, Blumenschein U, Boehnlein A, Boeriu O, Bolton TA, Bonamy P, Borcherding F, Borissov G, Bos K, Bose T, Boswell C, Brandt A, Briskin G, Brock R, Brooijmans G, Bross A, Buchanan NJ, Buchholz D, Buehler M, Buescher V, Burdin S, Burnett TH, Busato E, Butler JM, Bystricky J, Canelli F, Carvalho W, Casey BCK, Casey D, Cason NM, Castilla-Valdez H, Chakrabarti S, Chakraborty D, Chan KM, Chandra A, Chapin D, Charles F, Cheu E, Chevalier L, Cho DK, Choi S, Chopra S, Christiansen T, Christofek L, Claes D, Clark AR, Clément B, Clément C, Coadou Y, Colling DJ, Coney L, Connolly B, Cooke M, Cooper WE, Coppage D, Corcoran M, Coss J, Cothenet A, Cousinou MC, Crépé-Renaudin S, Cristetiu M, Cummings MAC, Cutts D, da Motta H, Davies B, Davies G, Davis GA, De K, de Jong P, de Jong SJ, De La Cruz-Burelo E, Martins CDO, Dean S, Del Signore K, Déliot F, Delsart PA, Demarteau M, Demina R, Demine P, Denisov D, Denisov SP, Desai S, Diehl HT, Diesburg M, Doidge M, Dong H, Doulas S, Duflot L, Dugad SR, Duperrin A, Dyer J, Dyshkant A, Eads M, Edmunds D, Edwards T, Ellison J, Elmsheuser J, Eltzroth JT, Elvira VD, Eno S, Ermolov P, Eroshin OV, Estrada J, Evans D, Evans H, Evdokimov A, Evdokimov VN, Fast J, Fatakia SN, Fein D, Feligioni L, Ferbel T, Fiedler F, Filthaut F, Fisher W, Fisk HE, Fleuret F, Fortner M, Fox H, Freeman W, Fu S, Fuess S, Galea CF, Gallas E, Galyaev E, Gao M, Garcia C, Garcia-Bellido A, Gardner J, Gavrilov V, Gay P, Gelé D, Gelhaus R, Genser K, Gerber CE, Gershtein Y, Geurkov G, Ginther G, Goldmann K, Golling T, Gómez B, Gounder K, Goussiou A, Graham G, Grannis PD, Greder S, Green JA, Greenlee H, Greenwood ZD, Gregores EM, Grinstein S, Gris P, Grivaz JF, Groer L, Grünendahl S, Grünewald MW, Gu W, Gurzhiev SN, Gutierrez G, Gutierrez P, Haas A, Hadley NJ, Haggerty H, Hagopian S, Hall I, Hall RE, Han C, Han L, Hanagaki K, Hanlet P, Harder K, Harrington R, Hauptman JM, Hauser R, Hays C, Hays J, Hebbeker T, Hebert C, Hedin D, Heinmiller JM, Heinson AP, Heintz U, Hensel C, Hesketh G, Hildreth MD, Hirosky R, Hobbs JD, Hoeneisen B, Hohlfeld M, Hong SJ, Hooper R, Hou S, Houben P, Hu Y, Huang J, Huang Y, Iashvili I, Illingworth R, Ito AS, Jabeen S, Jaffré M, Jain S, Jain V, Jakobs K, Jenkins A, Jesik R, Jiang Y, Johns K, Johnson M, Johnson P, Jonckheere A, Jonsson P, Jöstlein H, Juste A, Kado MM, Käfer D, Kahl W, Kahn S, Kajfasz E, Kalinin AM, Kalk J, Karmanov D, Kasper J, Kau D, Ke Z, Kehoe R, Kermiche S, Kesisoglou S, Khanov A, Kharchilava A, Kharzheev YM, Kim KH, Klima B, Klute M, Kohli JM, Kopal M, Korablev VM, Kotcher J, Kothari B, Kotwal AV, Koubarovsky A, Kouznetsov O, Kozelov AV, Kozminski J, Krane J, Krishnaswamy MR, Krzywdzinski S, Kubantsev M, Kuleshov S, Kulik Y, Kunori S, Kupco A, Kurca T, Kuznetsov VE, Lager S, Lahrichi N, Landsberg G, Lazoflores J, Le Bihan AC, Lebrun P, Lee SW, Lee WM, Leflat A, Leggett C, Lehner F, Leonidopoulos C, Lewis P, Li J, Li QZ, Li X, Lima JGR, Lincoln D, Linn SL, Linnemann J, Lipaev VV, Lipton R, Lobo L, Lobodenko A, Lokajicek M, Lounis A, Lu J, Lubatti HJ, Lucotte A, Lueking L, Luo C, Lynker M, Lyon AL, Maciel AKA, Madaras RJ, Mättig P, Magerkurth A, Magnan AM, Maity M, Makovec N, Mal PK, Malik S, Malyshev VL, Manankov V, Mao HS, Maravin Y, Marshall T, Martens M, Martin MI, Mattingly SEK, Mayorov AA, McCarthy R, McCroskey R, McMahon T, Meder D, Melanson HL, Melnitchouk A, Meng X, Merkin M, Merritt KW, Meyer A, Miao C, Miettinen H, Mihalcea D, Mitrevski J, Mokhov N, Molina J, Mondal NK, Montgomery HE, Moore RW, Mostafa M, Muanza GS, Mulders M, Mutaf YD, Nagy E, Nang F, Narain M, Narasimham VS, Naumann NA, Neal HA, Negret JP, Nelson S, Neustroev P, Noeding C, Nomerotski A, Novaes SF, Nunnemann T, Nurse E, O'Dell V, O'Neil DC, Oguri V, Oliveira N, Olivier B, Oshima N, Otero y Garzón GJ, Padley P, Papageorgiou K, Parashar N, Park J, Park SK, Parsons J, Partridge R, Parua N, Patwa A, Perea PM, Perez E, Peters O, Pétroff P, Petteni M, Phaf L, Piegaia R, Podesta-Lerma PLM, Podstavkov VM, Pogorelov Y, Pope BG, Popkov E, Prado da Silva WL, Prosper HB, Protopopescu S, Przybycien MB, Qian J, Quadt A, Quinn B, Rani KJ, Rapidis PA, Ratoff PN, Reay NW, Renardy JF, Reucroft S, Rha J, Ridel M, Rijssenbeek M, Ripp-Baudot I, Rizatdinova F, Royon C, Rubinov P, Ruchti R, Sabirov BM, Sajot G, Sánchez-Hernández A, Sanders MP, Santoro A, Savage G, Sawyer L, Scanlon T, Schamberger RD, Schellman H, Schieferdecker P, Schmitt C, Schukin AA, Schwartzman A, Schwienhorst R, Sengupta S, Severini H, Shabalina E, Shary V, Shephard WD, Shpakov D, Sidwell RA, Simak V, Sirotenko V, Skow D, Skubic P, Slattery P, Smith RP, Smolek K, Snow GR, Snow J, Snyder S, Söldner-Rembold S, Song X, Song Y, Sonnenschein L, Sopczak A, Sorín V, Sosebee M, Soustruznik K, Souza M, Spurlock B, Stanton NR, Stark J, Steele J, Steinbrück G, Stevenson K, Stolin V, Stone A, Stoyanova DA, Strandberg J, Strang MA, Strauss M, Ströhmer R, Strovink M, Stutte L, Sumowidagdo S, Sznajder A, Talby M, Tamburello P, Taylor W, Telford P, Temple J, Tentindo-Repond S, Thomas E, Thooris B, Tomoto M, Toole T, Torborg J, Towers S, Trefzger T, Trincaz-Duvoid S, Trippe TG, Tuchming B, Tully C, Turcot AS, Tuts PM, Uvarov L, Uvarov S, Uzunyan S, Vachon B, Van Kooten R, van Leeuwen WM, Varelas N, Varnes EW, Vasilyev IA, Vaupel M, Verdier P, Vertogradov LS, Verzocchi M, Villeneuve-Seguier F, Vlimant JR, Von Toerne E, Vreeswijk M, Vu Anh T, Wahl HD, Walker R, Wallace N, Wang ZM, Warchol J, Warsinsky M, Watts G, Wayne M, Weber M, Weerts H, Wegner M, Wermes N, White A, White V, Whiteson D, Wicke D, Wijngaarden DA, Wilson GW, Wimpenny SJ, Wittlin J, Wlodek T, Wobisch M, Womersley J, Wood DR, Wu Z, Wyatt TR, Xu Q, Xuan N, Yamada R, Yan M, Yasuda T, Yatsunenko YA, Yen Y, Yip K, Youn SW, Yu J, Yurkewicz A, Zabi A, Zatserklyaniy A, Zdrazil M, Zeitnitz C, Zhang B, Zhang D, Zhang X, Zhao T, Zhao Z, Zheng H, Zhou B, Zhou Z, Zhu J, Zielinski M, Zieminska D, Zieminski A, Zitoun R, Zutshi V, Zverev EG, Zylberstejn A. Measurement of dijet azimuthal decorrelations at central rapidities in pp collisions at sqrt s =1.96 TeV. PHYSICAL REVIEW LETTERS 2005; 94:221801. [PMID: 16090381 DOI: 10.1103/physrevlett.94.221801] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/16/2004] [Indexed: 05/03/2023]
Abstract
Correlations in the azimuthal angle between the two largest transverse momentum jets have been measured using the D0 detector in p (-)p collisions at a center-of-mass energy sqrt[s]=1.96 TeV. The analysis is based on an inclusive dijet event sample in the central rapidity region corresponding to an integrated luminosity of 150 pb(-1). Azimuthal correlations are stronger at larger transverse momenta. These are well described in perturbative QCD at next-to-leading order in the strong coupling constant, except at large azimuthal differences where contributions with low transverse momentum are significant.
Collapse
|
515
|
Mandel SA, Avramovich-Tirosh Y, Reznichenko L, Zheng H, Weinreb O, Amit T, Youdim MBH. Multifunctional Activities of Green Tea Catechins in Neuroprotection. Neurosignals 2005; 14:46-60. [PMID: 15956814 DOI: 10.1159/000085385] [Citation(s) in RCA: 242] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2005] [Accepted: 03/01/2005] [Indexed: 12/16/2022] Open
Abstract
Many lines of evidence suggest that oxidative stress resulting in reactive oxygen species (ROS) generation and inflammation play a pivotal role in the age-associated cognitive decline and neuronal loss in neurodegenerative diseases including Alzheimer's (AD), Parkinson's (PD) and Huntington's diseases. One cardinal chemical pathology observed in these disorders is the accumulation of iron at sites where the neurons die. The buildup of an iron gradient in conjunction with ROS (superoxide, hydroxyl radical and nitric oxide) are thought to constitute a major trigger in neuronal toxicity and demise in all these diseases. Thus, promising future treatment of neurodegenerative diseases and aging depends on availability of effective brain permeable, iron-chelatable/radical scavenger neuroprotective drugs that would prevent the progression of neurodegeneration. Tea flavonoids (catechins) have been reported to possess potent iron-chelating, radical-scavenging and anti-inflammatory activities and to protect neuronal death in a wide array of cellular and animal models of neurological diseases. Recent studies have indicated that in addition to the known antioxidant activity of catechins, other mechanisms such as modulation of signal transduction pathways, cell survival/death genes and mitochondrial function, contribute significantly to the induction of cell viability. This review will focus on the multifunctional properties of green tea and its major component (-)-epigallocatechin-3-gallate (EGCG) and their ability to induce neuroprotection and neurorescue in vitro and in vivo. In particular, their transitional metal (iron and copper) chelating property and inhibition of oxidative stress.
Collapse
|
516
|
|
517
|
Zhao T, Shinde SR, Ogale SB, Zheng H, Venkatesan T, Ramesh R, Das Sarma S. Electric field effect in diluted magnetic insulator anatase Co: TiO2. PHYSICAL REVIEW LETTERS 2005; 94:126601. [PMID: 15903943 DOI: 10.1103/physrevlett.94.126601] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/06/2004] [Revised: 12/06/2004] [Indexed: 05/02/2023]
Abstract
An external electric field induced reversible modulation of a room temperature magnetic moment and coercive field is achieved in an epitaxial and insulating thin film of dilutely cobalt-doped anatase TiO2. This first demonstration of an electric field effect in any oxide-based diluted ferromagnet is realized in a high quality epitaxial heterostructure of PbZr(0.2)Ti(0.8)O(3)/Co: TiO(2)/SrRuO(3) grown on (001) LaAlO3. The observed effect, which is about 15% in strength in a given heterostructure, can be modulated over several cycles. Possible mechanisms for electric field induced modulation of insulating ferromagnetism are discussed.
Collapse
|
518
|
Bilbao R, Reay DP, Wu E, Zheng H, Biermann V, Kochanek S, Clemens PR. Comparison of high-capacity and first-generation adenoviral vector gene delivery to murine muscle in utero. Gene Ther 2005; 12:39-47. [PMID: 15483668 DOI: 10.1038/sj.gt.3302392] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
In utero gene delivery could offer the advantage of treatment at an early stage for genetic disorders such as Duchenne muscular dystrophy (DMD) in which the inevitable process of muscle degeneration is already initiated at birth. Furthermore, treatment of fetal muscle with adenoviral (Ad) vectors is attractive because of a high density of Ad receptors, easy vector accessibility due to immaturity of the basal lamina and the possibility of treating stem cells. Previously, we demonstrated the efficient transduction of fetal muscle by high-capacity Ad (HC-Ad) vectors. In this study, we compared HC-Ad and first-generation Ad (FG-Ad) vectors for longevity of lacZ transgene expression, toxicity and induction of immunity after direct vector-mediated in utero gene delivery to fetal C57BL/6 mice muscle 16 days after conception (E-16). The total amount of beta-galactosidase (betagal) expressed from the HC-Ad vector remained stable for the 5 months of the study, although the concentration of betagal decreased due to muscle growth. Higher survival rates that reflect lower levels of toxicity were observed in those mice transduced with an HC-Ad vector as compared to an FG-Ad vector. The toxicity induced by FG-Ad vector gene delivery was dependent on mouse strain and vector dose. Animals treated with either HC-Ad and FG-Ad vectors developed non-neutralizing antibodies against Ad capsid and antibodies against betagal, but these antibodies did not cause loss of vector genomes from transduced muscle. In a mouse model of DMD, dystrophin gene transfer to muscle in utero using an HC-Ad vector restored the dystrophin-associated glycoproteins. Our results demonstrate that long-term transgene expression can be achieved by HC-Ad vector-mediated gene delivery to fetal muscle, although strategies of vector integration may need to be considered to accommodate muscle growth.
Collapse
|
519
|
Wang J, Scholl A, Zheng H, Ogale SB, Viehland D, Schlom DG, Spaldin NA, Rabe KM, Wuttig M, Mohaddes L, Neaton J, Waghmare U, Zhao T, Ramesh R. Response to Comment on "Epitaxial BiFeO
3
Multiferroic Thin Film Heterostructures". Science 2005. [DOI: 10.1126/science.1103959] [Citation(s) in RCA: 180] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
520
|
Abazov VM, Abbott B, Abolins M, Acharya BS, Adams DL, Adams M, Adams T, Agelou M, Agram JL, Ahmed SN, Ahn SH, Alexeev GD, Alkhazov G, Alton A, Alverson G, Alves GA, Anderson S, Andrieu B, Arnoud Y, Askew A, Asman B, Atramentov O, Autermann C, Avila C, Babukhadia L, Bacon TC, Baden A, Baffioni S, Baldin B, Balm PW, Banerjee S, Barberis E, Bargassa P, Baringer P, Barnes C, Barreto J, Bartlett JF, Bassler U, Bauer D, Bean A, Beauceron S, Beaudette F, Begel M, Bellavance A, Beri SB, Bernardi G, Bernhard R, Bertram I, Besançon M, Besson A, Beuselinck R, Bezzubov VA, Bhat PC, Bhatnagar V, Bhattacharjee M, Binder M, Bischoff A, Black KM, Blackler I, Blazey G, Blekman F, Bloch D, Blumenschein U, Boehnlein A, Boeriu O, Bolton TA, Bonamy P, Borcherding F, Borissov G, Bos K, Bose T, Boswell C, Brandt A, Briskin G, Brock R, Brooijmans G, Bross A, Buchanan NJ, Buchholz D, Buehler M, Buescher V, Burdin S, Burnett TH, Busato E, Butler JM, Bystricky J, Canelli F, Carvalho W, Casey BCK, Casey D, Cason NM, Castilla-Valdez H, Chakrabarti S, Chakraborty D, Chan KM, Chandra A, Chapin D, Charles F, Cheu E, Chevalier L, Cho DK, Choi S, Chopra S, Christiansen T, Christofek L, Claes D, Clark AR, Clément B, Clément C, Coadou Y, Colling DJ, Coney L, Connolly B, Cooke M, Cooper WE, Coppage D, Corcoran M, Coss J, Cothenet A, Cousinou MC, Crépé-Renaudin S, Cristetiu M, Cummings MAC, Cutts D, da Motta H, Davies B, Davies G, Davis GA, De K, de Jong P, de Jong SJ, De La Cruz-Burelo E, De Oliveira Martins C, Dean S, Del Signore K, Déliot F, Delsart PA, Demarteau M, Demina R, Demine P, Denisov D, Denisov SP, Desai S, Diehl HT, Diesburg M, Doidge M, Dong H, Doulas S, Duflot L, Dugad SR, Duperrin A, Dyer J, Dyshkant A, Eads M, Edmunds D, Edwards T, Ellison J, Elmsheuser J, Eltzroth JT, Elvira VD, Eno S, Ermolov P, Eroshin OV, Estrada J, Evans D, Evans H, Evdokimov A, Evdokimov VN, Fast J, Fatakia SN, Fein D, Feligioni L, Ferbel T, Fiedler F, Filthaut F, Fisher W, Fisk HE, Fleuret F, Fortner M, Fox H, Freeman W, Fu S, Fuess S, Galea CF, Gallas E, Galyaev E, Gao M, Garcia C, Garcia-Bellido A, Gardner J, Gavrilov V, Gelé D, Gelhaus R, Genser K, Gerber CE, Gershtein Y, Geurkov G, Ginther G, Goldmann K, Golling T, Gómez B, Gounder K, Goussiou A, Graham G, Grannis PD, Greder S, Green JA, Greenlee H, Greenwood ZD, Gregores EM, Grinstein S, Grivaz JF, Groer L, Grünendahl S, Grünewald MW, Gu W, Gurzhiev SN, Gutierrez G, Gutierrez P, Haas A, Hadley NJ, Haggerty H, Hagopian S, Hall I, Hall RE, Han C, Han L, Hanagaki K, Hanlet P, Harder K, Harrington R, Hauptman JM, Hauser R, Hays C, Hays J, Hebbeker T, Hebert C, Hedin D, Heinmiller JM, Heinson AP, Heintz U, Hensel C, Hesketh G, Hildreth MD, Hirosky R, Hobbs JD, Hoeneisen B, Hohlfeld M, Hong SJ, Hooper R, Hou S, Hu Y, Huang J, Huang Y, Iashvili I, Illingworth R, Ito AS, Jabeen S, Jaffré M, Jain S, Jain V, Jakobs K, Jenkins A, Jesik R, Jiang Y, Johns K, Johnson M, Johnson P, Jonckheere A, Jonsson P, Jöstlein H, Juste A, Kado MM, Käfer D, Kahl W, Kahn S, Kajfasz E, Kalinin AM, Kalk J, Karmanov D, Kasper J, Kau D, Ke Z, Kehoe R, Kermiche S, Kesisoglou S, Khanov A, Kharchilava A, Kharzheev YM, Kim KH, Klima B, Klute M, Kohli JM, Kopal M, Korablev VM, Kotcher J, Kothari B, Kotwal AV, Koubarovsky A, Kouchner A, Kouznetsov O, Kozelov AV, Kozminski J, Krane J, Krishnaswamy MR, Krzywdzinski S, Kubantsev M, Kuleshov S, Kulik Y, Kunori S, Kupco A, Kurca T, Kuznetsov VE, Lager S, Lahrichi N, Landsberg G, Lazoflores J, Le Bihan AC, Lebrun P, Lee SW, Lee WM, Leflat A, Leggett C, Lehner F, Leonidopoulos C, Lewis P, Li J, Li QZ, Li X, Lima JGR, Lincoln D, Linn SL, Linnemann J, Lipaev VV, Lipton R, Lobo L, Lobodenko A, Lokajicek M, Lounis A, Lu J, Lubatti HJ, Lucotte A, Lueking L, Luo C, Lynker M, Lyon AL, Maciel AKA, Madaras RJ, Mättig P, Magerkurth A, Magnan AM, Maity M, Mal PK, Malik S, Malyshev VL, Manankov V, Mao HS, Maravin Y, Marshall T, Martens M, Martin MI, Mattingly SEK, Mayorov AA, McCarthy R, McCroskey R, McMahon T, Meder D, Melanson HL, Melnitchouk A, Meng X, Merkin M, Merritt KW, Meyer A, Miao C, Miettinen H, Mihalcea D, Mishra CS, Mitrevski J, Mokhov N, Molina J, Mondal NK, Montgomery HE, Moore RW, Mostafa M, Muanza GS, Mulders M, Mutaf YD, Nagy E, Nang F, Narain M, Narasimham VS, Naumann NA, Neal HA, Negret JP, Nelson S, Neustroev P, Noeding C, Nomerotski A, Novaes SF, Nunnemann T, Nurse E, O'Dell V, O'Neil DC, Oguri V, Oliveira N, Olivier B, Oshima N, Otero y Garzón GJ, Padley P, Papageorgiou K, Parashar N, Park J, Park SK, Parsons J, Partridge R, Parua N, Patwa A, Perea PM, Perez E, Peters O, Pétroff P, Petteni M, Phaf L, Piegaia R, Podesta-Lerma PLM, Podstavkov VM, Pope BG, Popkov E, Prado da Silva WL, Prosper HB, Protopopescu S, Przybycien MB, Qian J, Quadt A, Quinn B, Rani KJ, Rapidis PA, Ratoff PN, Reay NW, Renardy JF, Reucroft S, Rha J, Ridel M, Rijssenbeek M, Ripp-Baudot I, Rizatdinova F, Royon C, Rubinov P, Ruchti R, Sabirov BM, Sajot G, Sánchez-Hernández A, Sanders MP, Santoro A, Savage G, Sawyer L, Scanlon T, Schamberger RD, Schellman H, Schieferdecker P, Schmitt C, Schukin AA, Schwartzman A, Schwienhorst R, Sengupta S, Severini H, Shabalina E, Shary V, Shephard WD, Shpakov D, Sidwell RA, Simak V, Sirotenko V, Skow D, Skubic P, Slattery P, Smith RP, Smolek K, Snow GR, Snow J, Snyder S, Söldner-Rembold S, Song X, Song Y, Sonnenschein L, Sopczak A, Sorín V, Sosebee M, Soustruznik K, Souza M, Spurlock B, Stanton NR, Stark J, Steele J, Steinbrück G, Stevenson K, Stolin V, Stone A, Stoyanova DA, Strandberg J, Strang MA, Strauss M, Ströhmer R, Strovink M, Stutte L, Sznajder A, Talby M, Tamburello P, Taylor W, Telford P, Temple J, Tentindo-Repond S, Thomas E, Thooris B, Tomoto M, Toole T, Torborg J, Towers S, Trefzger T, Trincaz-Duvoid S, Trippe TG, Tuchming B, Tully C, Turcot AS, Tuts PM, Uvarov L, Uvarov S, Uzunyan S, Vachon B, Van Kooten R, van Leeuwen WM, Varelas N, Varnes EW, Vasilyev IA, Vaupel M, Verdier P, Vertogradov LS, Verzocchi M, Villeneuve-Seguier F, Vlimant JR, Von Toerne E, Vreeswijk M, Vu Anh T, Wahl HD, Walker R, Wallace N, Wang ZM, Warchol J, Warsinsky M, Watts G, Wayne M, Weber M, Weerts H, Wegner M, Wermes N, White A, White V, Whiteson D, Wicke D, Wijngaarden DA, Wilson GW, Wimpenny SJ, Wittlin J, Wlodek T, Wobisch M, Womersley J, Wood DR, Wu Z, Wyatt TR, Xu Q, Xuan N, Yamada R, Yasuda T, Yatsunenko YA, Yen Y, Yip K, Youn SW, Yu J, Yurkewicz A, Zabi A, Zatserklyaniy A, Zdrazil M, Zeitnitz C, Zhang B, Zhang D, Zhang X, Zhao T, Zhao Z, Zheng H, Zhou B, Zhou Z, Zhu J, Zielinski M, Zieminska D, Zieminski A, Zitoun R, Zutshi V, Zverev EG, Zylberstejn A. Search for supersymmetry with gauge-mediated breaking in diphoton events at D0. PHYSICAL REVIEW LETTERS 2005; 94:041801. [PMID: 15783547 DOI: 10.1103/physrevlett.94.041801] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/30/2004] [Indexed: 05/24/2023]
Abstract
We report the results of a search for supersymmetry (SUSY) with gauge-mediated breaking in the missing transverse energy distribution of inclusive diphoton events using 263 pb(-1) of data collected by the D0 experiment at the Fermilab Tevatron Collider in 2002-2004. No excess is observed above the background expected from standard model processes, and lower limits on the masses of the lightest neutralino and chargino of about 108 and 195 GeV, respectively, are set at the 95% confidence level. These are the most stringent limits to date for models with gauge-mediated SUSY breaking with a short-lived neutralino as the next-to-lightest SUSY particle.
Collapse
|
521
|
Abazov VM, Abbott B, Abolins M, Acharya BS, Adams DL, Adams M, Adams T, Agelou M, Agram JL, Ahmed SN, Ahn SH, Alexeev GD, Alkhazov G, Alton A, Alverson G, Alves GA, Anastasoaie M, Anderson S, Andrieu B, Arnoud Y, Askew A, Asman B, Atramentov O, Autermann C, Avila C, Babukhadia L, Bacon TC, Badaud F, Baden A, Baffioni S, Baldin B, Balm PW, Banerjee S, Barberis E, Bargassa P, Baringer P, Barnes C, Barreto J, Bartlett JF, Bassler U, Bauer D, Bean A, Beauceron S, Beaudette F, Begel M, Bellavance A, Beri SB, Bernardi G, Bernhard R, Bertram I, Besançon M, Besson A, Beuselinck R, Bezzubov VA, Bhat PC, Bhatnagar V, Bhattacharjee M, Binder M, Bischoff A, Black KM, Blackler I, Blazey G, Blekman F, Blessing S, Bloch D, Blumenschein U, Boehnlein A, Boeriu O, Bolton TA, Bonamy P, Borcherding F, Borissov G, Bos K, Bose T, Boswell C, Brandt A, Briskin G, Brock R, Brooijmans G, Bross A, Buchanan NJ, Buchholz D, Buehler M, Buescher V, Burdin S, Burnett TH, Busato E, Butler JM, Bystricky J, Canelli F, Carvalho W, Casey BCK, Casey D, Cason NM, Castilla-Valdez H, Chakrabarti S, Chakraborty D, Chan KM, Chandra A, Chapin D, Charles F, Cheu E, Chevalier L, Cho DK, Choi S, Chopra S, Christiansen T, Christofek L, Claes D, Clark AR, Clément B, Clément C, Coadou Y, Colling DJ, Coney L, Connolly B, Cooke M, Cooper WE, Coppage D, Corcoran M, Coss J, Cothenet A, Cousinou MC, Crépé-Renaudin S, Cristetiu M, Cummings MAC, Cutts D, da Motta H, Davies B, Davies G, Davis GA, De K, de Jong P, de Jong SJ, De La Cruz-Burelo E, De Oliveira Martins C, Dean S, Del Signore K, Déliot F, Delsart PA, Demarteau M, Demina R, Demine P, Denisov D, Denisov SP, Desai S, Diehl HT, Diesburg M, Doidge M, Dong H, Doulas S, Duflot L, Dugad SR, Duperrin A, Dyer J, Dyshkant A, Eads M, Edmunds D, Edwards T, Ellison J, Elmsheuser J, Eltzroth JT, Elvira VD, Eno S, Ermolov P, Eroshin OV, Estrada J, Evans D, Evans H, Evdokimov A, Evdokimov VN, Fast J, Fatakia SN, Fein D, Feligioni L, Ferbel T, Fiedler F, Filthaut F, Fisher W, Fisk HE, Fleuret F, Fortner M, Fox H, Freeman W, Fu S, Fuess S, Galea CF, Gallas E, Galyaev E, Gao M, Garcia C, Garcia-Bellido A, Gardner J, Gavrilov V, Gay P, Gelé D, Gelhaus R, Genser K, Gerber CE, Gershtein Y, Geurkov G, Ginther G, Goldmann K, Golling T, Gómez B, Gounder K, Goussiou A, Graham G, Grannis PD, Greder S, Green JA, Greenlee H, Greenwood ZD, Gregores EM, Grinstein S, Gris P, Grivaz JF, Groer L, Grünendahl S, Grünewald MW, Gu W, Gurzhiev SN, Gutierrez G, Gutierrez P, Haas A, Hadley NJ, Haggerty H, Hagopian S, Hall I, Hall RE, Han C, Han L, Hanagaki K, Hanlet P, Harder K, Harrington R, Hauptman JM, Hauser R, Hays C, Hays J, Hebbeker T, Hebert C, Hedin D, Heinmiller JM, Heinson AP, Heintz U, Hensel C, Hesketh G, Hildreth MD, Hirosky R, Hobbs JD, Hoeneisen B, Hohlfeld M, Hong SJ, Hooper R, Hou S, Houben P, Hu Y, Huang J, Huang Y, Iashvili I, Illingworth R, Ito AS, Jabeen S, Jaffré M, Jain S, Jain V, Jakobs K, Jenkins A, Jesik R, Jiang Y, Johns K, Johnson M, Johnson P, Jonckheere A, Jonsson P, Jöstlein H, Juste A, Kado MM, Käfer D, Kahl W, Kahn S, Kajfasz E, Kalinin AM, Kalk J, Karmanov D, Kasper J, Kau D, Ke Z, Kehoe R, Kermiche S, Kesisoglou S, Khanov A, Kharchilava A, Kharzheev YM, Kim KH, Klima B, Klute M, Kohli JM, Kopal M, Korablev VM, Kotcher J, Kothari B, Kotwal AV, Koubarovsky A, Kouznetsov O, Kozelov AV, Kozminski J, Krane J, Krishnaswamy MR, Krzywdzinski S, Kubantsev M, Kuleshov S, Kulik Y, Kunori S, Kupco A, Kurca T, Kuznetsov VE, Lager S, Lahrichi N, Landsberg G, Lazoflores J, Le Bihan AC, Lebrun P, Lee SW, Lee WM, Leflat A, Leggett C, Lehner F, Leonidopoulos C, Lewis P, Li J, Li QZ, Li X, Lima JGR, Lincoln D, Linn SL, Linnemann J, Lipaev VV, Lipton R, Lobo L, Lobodenko A, Lokajicek M, Lounis A, Lu J, Lubatti HJ, Lucotte A, Lueking L, Luo C, Lynker M, Lyon AL, Maciel AKA, Madaras RJ, Mättig P, Magerkurth A, Magnan AM, Maity M, Makovec N, Mal PK, Malik S, Malyshev VL, Manankov V, Mao HS, Maravin Y, Marshall T, Martens M, Martin MI, Mattingly SEK, Mayorov AA, McCarthy R, McCroskey R, McMahon T, Meder D, Melanson HL, Melnitchouk A, Meng X, Merkin M, Merritt KW, Meyer A, Miao C, Miettinen H, Mihalcea D, Mitrevski J, Mokhov N, Molina J, Mondal NK, Montgomery HE, Moore RW, Mostafa M, Muanza GS, Mulders M, Mutaf YD, Nagy E, Nang F, Narain M, Narasimham VS, Naumann NA, Neal HA, Negret JP, Nelson S, Neustroev P, Noeding C, Nomerotski A, Novaes SF, Nunnemann T, Nurse E, O'Dell V, O'Neil DC, Oguri V, Oliveira N, Olivier B, Oshima N, Otero y Garzón GJ, Padley P, Papageorgiou K, Parashar N, Park J, Park SK, Parsons J, Partridge R, Parua N, Patwa A, Perea PM, Perez E, Peters O, Pétroff P, Petteni M, Phaf L, Piegaia R, Podesta-Lerma PLM, Podstavkov VM, Pogorelov Y, Pope BG, Popkov E, Prado da Silva WL, Prosper HB, Protopopescu S, Przybycien MB, Qian J, Quadt A, Quinn B, Rani KJ, Rapidis PA, Ratoff PN, Reay NW, Renardy JF, Reucroft S, Rha J, Ridel M, Rijssenbeek M, Ripp-Baudot I, Rizatdinova F, Royon C, Rubinov P, Ruchti R, Sabirov BM, Sajot G, Sánchez-Hernández A, Sanders MP, Santoro A, Savage G, Sawyer L, Scanlon T, Schamberger RD, Schellman H, Schieferdecker P, Schmitt C, Schukin AA, Schwartzman A, Schwienhorst R, Sengupta S, Severini H, Shabalina E, Shary V, Shephard WD, Shpakov D, Sidwell RA, Simak V, Sirotenko V, Skow D, Skubic P, Slattery P, Smith RP, Smolek K, Snow GR, Snow J, Snyder S, Söldner-Rembold S, Song X, Song Y, Sonnenschein L, Sopczak A, Sorín V, Sosebee M, Soustruznik K, Souza M, Spurlock B, Stanton NR, Stark J, Steele J, Steinbrück G, Stevenson K, Stolin V, Stone A, Stoyanova DA, Strandberg J, Strang MA, Strauss M, Ströhmer R, Strovink M, Stutte L, Sumowidagdo S, Sznajder A, Talby M, Tamburello P, Taylor W, Telford P, Temple J, Tentindo-Repond S, Thomas E, Thooris B, Tomoto M, Toole T, Torborg J, Towers S, Trefzger T, Trincaz-Duvoid S, Trippe TG, Tuchming B, Tully C, Turcot AS, Tuts PM, Uvarov L, Uvarov S, Uzunyan S, Vachon B, Van Kooten R, van Leeuwen WM, Varelas N, Varnes EW, Vasilyev IA, Vaupel M, Verdier P, Vertogradov LS, Verzocchi M, Villeneuve-Seguier F, Von Vlimant JR, Toerne E, Vreeswijk M, Vu Anh T, Wahl HD, Walker R, Wallace N, Wang ZM, Warchol J, Warsinsky M, Watts G, Wayne M, Weber M, Weerts H, Wegner M, Wermes N, White A, White V, Whiteson D, Wicke D, Wijngaarden DA, Wilson GW, Wimpenny SJ, Wittlin J, Wlodek T, Wobisch M, Womersley J, Wood DR, Wu Z, Wyatt TR, Xu Q, Xuan N, Yamada R, Yan M, Yasuda T, Yatsunenko YA, Yen Y, Yip K, Youn SW, Yu J, Yurkewicz A, Zabi A, Zatserklyaniy A, Zdrazil M, Zeitnitz C, Zhang B, Zhang D, Zhang X, Zhao T, Zhao Z, Zheng H, Zhou B, Zhou Z, Zhu J, Zielinski M, Zieminska D, Zieminski A, Zitoun R, Zutshi V, Zverev EG, Zylberstejn A. Measurement of the B0s lifetime in the exclusive decay channel B0s-->J/psiphi. PHYSICAL REVIEW LETTERS 2005; 94:042001. [PMID: 15783550 DOI: 10.1103/physrevlett.94.042001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/22/2004] [Indexed: 05/24/2023]
Abstract
Using the exclusive decay B0s-->J/psi(mu+mu-)phi(K+K-), we report the most precise single measurement of the B0s lifetime. The data sample corresponds to an integrated luminosity of approximately 220 pb(-1) collected with the D0 detector at the Fermilab Tevatron Collider in 2002-2004. We reconstruct 337 signal candidates, from which we extract the B0s lifetime, tau(B0s)=1.444(+0.098)(-0.090)(stat)+/-0.020(sys) ps. We also report a measurement for the lifetime of the B0 meson using the exclusive decay B0-->J/psi(mu+mu-)K*0(892)(K+pi-). We reconstruct 1370 signal candidates, obtaining tau(B0)=1.473(+0.052)(-0.050)(stat)+/-0.023(sys) ps, and the ratio of lifetimes, tau(B0s)/tau(B0)=0.980(+0.076)(-0.071)(stat)+/-0.003(sys).
Collapse
|
522
|
Youdim MBH, Fridkin M, Zheng H. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. Mech Ageing Dev 2005; 126:317-26. [PMID: 15621213 DOI: 10.1016/j.mad.2004.08.023] [Citation(s) in RCA: 95] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Degeneration of nigrostriatal dopamine neurons and cholinergic cortical neurones are the main pathological features of Parkinson's disease (PD) and for the cognitive deficit in dementia of the Alzheimer' type (AD) and in dementia with Lewy bodies (DLB), respectively. Many PD and DLB subjects have dementia and depression resulting from possible degeneration of cholinergic and noradrenergic and serotonergic neurons. On the other hand, AD patients may also develop extrapyramidal features as well as depression. In both PD and AD there is, respectively, accumulation of iron within the melanin containing dopamine neurons of pars compacta and with in the plaques and tangle. It has been suggested that iron accumulation may contribute to the oxidative stress induced apoptosis reported in both diseases. This may result from increased glia hydrogen peroxide producing monoamine oxidase (MAO) activity that can generate of reactive hydroxyl radical formed from interaction of iron and hydrogen peroxide. We have therefore prepared a series of novel bifunctional drugs from the neuroprotective-antiapoptotic antiparkinson monoamine oxidase B inhibitor, rasagiline, by introducing a carbamate cholinesterase (ChE) inhibitory moiety into it. Ladostigil (TV-3326, N-propargyl-3R-aminoindan-5yl)-ethyl methylcarbamate), has both ChE and MAO-AB inhibitory activity, as potential treatment of AD and DLB or PD subjects with dementia Being a brain selective MAO-AB inhibitor it has limited potentiation of the pressor response to oral tyramine and exhibits antidepressant activity similar to classical non-selective MAO inhibitor antidepressants by increasing brain serotonin and noradrenaline. Ladostigil inhibits brain acetyl and butyrylcholinesterase in rats and antagonizes scopolamine-induced inhibition of spatial learning. Ladostigil like MAO-B inhibitor it prevents MPTP Parkinsonism in mice model and retains the in vitro and in vivo neuroprotective activity of rasagiline. Ladostigil, rasagiline and other propargylamines have been demonstrated to have neuroprotective activity in several in vitro and in vivo models, which have been shown be associated with propargylamines moiety, since propargylamines itself possess these properties. The mechanism of neuroprotective activity has been attributed to the ability of propargylamines-inducing the antiapoptotic family proteins Bcl-2 and Bcl-xl, while decreasing Bad and Bax and preventing opening of mitochondrial permeability transition pore. Iron accumulates in brain regions associated with neurodegenerative diseases of PD, AD, amyotrophic lateral sclerosis and Huntington disease. It is thought to be involved in Fenton chemistry oxidative stress observed in these diseases. The neuroprotective activity of propargylamines led us to develop several novel bifunctional iron chelator from our prototype brain permeable iron chelators, VK-28, possessing propargylamine moiety (HLA-20, M30 and M30A) to iron out iron from the brain. These compounds have been shown to have iron chelating and monoamine oxidase A and B selective brain inhibitory and neuroprotective-antiapoptotic actions.
Collapse
|
523
|
Wu J, Lynn JW, Glinka CJ, Burley J, Zheng H, Mitchell JF, Leighton C. Intergranular giant magnetoresistance in a spontaneously phase separated perovskite oxide. PHYSICAL REVIEW LETTERS 2005; 94:037201. [PMID: 15698314 DOI: 10.1103/physrevlett.94.037201] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/09/2004] [Indexed: 05/24/2023]
Abstract
We present small-angle neutron scattering data proving that, on the insulating side of the metal-insulator transition, the doped perovskite cobaltite La(1-x)Sr(x)CoO(3) phase separates into ferromagnetic metallic clusters embedded in a nonferromagnetic matrix. This induces a hysteretic magnetoresistance, with temperature and field dependence characteristic of intergranular giant magnetoresistance (GMR). We argue that this system is a natural analog to the artificial structures fabricated by depositing nanoscale ferromagnetic particles in a metallic or insulating matrix; i.e., this material displays a GMR effect without the deliberate introduction of chemical interfaces.
Collapse
|
524
|
Wang J, Zheng H, Ou X, Albertson CM, Fink LM, Herbert JM, Hauer-Jensen M. Hirudin ameliorates intestinal radiation toxicity in the rat: support for thrombin inhibition as strategy to minimize side-effects after radiation therapy and as countermeasure against radiation exposure. J Thromb Haemost 2004; 2:2027-35. [PMID: 15550035 DOI: 10.1111/j.1538-7836.2004.00960.x] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
BACKGROUND The small bowel is a dose-limiting normal tissue in radiation therapy of malignancies in the abdomen and pelvis, as well as an important determinant of survival after non-therapeutic radiation exposure. Irradiation of normal tissues, including intestine, causes loss of vascular thromboresistance and upregulation of thrombin receptors. Radiation-induced endothelial dysfunction is thought to be involved in both early and delayed radiation responses. Hence, thrombin may be a potential target for ameliorating normal tissue radiation toxicity. OBJECTIVE To assess direct thrombin inhibition as a protective strategy against small bowel radiation toxicity. METHODS Rat small intestine was exposed to localized orthovoltage X-radiation. Recombinant hirudin, a direct thrombin inhibitor, or vehicle was infused from 2 days before irradiation to 14 days after irradiation. Structural, cellular, and molecular aspects of intestinal radiation injury were assessed at 2 weeks (early toxicity) and 26 weeks (chronic toxicity) after irradiation. RESULTS Compared with unirradiated intestine, irradiated intestine showed increased expression of tissue factor, increased immunoreactivity for enzymatically active thrombin, and increased extravascular fibrin(ogen) deposition. Hirudin treatment significantly attenuated radiation-induced mucosal damage (P = 0.04), reactive intestinal wall thickening (P = 0.02), transforming growth factor-beta immunoreactivity levels (P = 0.0002), and collagen III deposition (P = 0.003). The differences between hirudin-treated and control rats were more pronounced at 2 weeks than at 26 weeks after irradiation. Hirudin treatment did not affect postradiation granulocyte infiltration. CONCLUSIONS Short-term thrombin inhibition attenuates important aspects of intestinal radiation toxicity. Thrombin is a promising target for minimizing normal tissue injury after radiation therapy of cancer, as well as for protecting normal tissues from the adverse effects of non-therapeutic radiation exposure.
Collapse
|
525
|
Sun Z, Zheng H. Effect of Suprarenal Stent Struts on the Renal Artery with Ostial Calcification Observed on CT Virtual Intravascular Endoscopy. Eur J Vasc Endovasc Surg 2004; 28:534-42. [PMID: 15465376 DOI: 10.1016/j.ejvs.2004.08.005] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/26/2004] [Indexed: 11/26/2022]
Abstract
OBJECTIVES The behaviour of stent struts crossing the renal ostia and their effect on renal ostia configuration is not well understood. The study aims to investigate whether suprarenal stent struts affect the morphological change of the renal artery with ostial calcification observed on CT virtual intravascular endoscopy. METHODS Nine patients with abdominal aortic aneurysms undergoing suprarenal fixation of stent grafts were included in the study. All patients received a Zenith endovascular graft with uncovered suprarenal components placed above the renal arteries. Renal ostial calcification and configuration of stent wires crossing the renal ostium were characterized in each patient and maximal transverse and longitudinal diameters of the renal ostia were measured on virtual endoscopy pre- and post-stent grafting. RESULTS There were altogether 17 renal ostia assessed with one patient having atrophic left kidney and no renal ostium being observed. Ostial calcification was found in five of the left renal ostia and five of the right renal ostia with one patient having bilateral ostial calcification. There was no significant difference between the renal ostial diameters measured pre- and post-stent grafting (p>0.05). Suprarenal stent struts were found to cross the renal ostia in various configurations observed on virtual endoscopy. All of the renal arteries were patent on follow-up CT scans after suprarenal fixation without stenosis or occlusion being observed. One patient with atrophic left renal artery developed renal failure following suprarenal stent grafting and received renal dialysis, while in the remaining cases median serum creatinine level did not change significantly. CONCLUSIONS Suprarenal stent struts did not significantly affect the renal ostia with ostial calcification in terms of the diameter measurements and renal function. Further studies deserve to investigate the long-term effect of stent struts on the renal artery in terms of cross-sectional area reduction caused by stent wires and ostial calcification.
Collapse
|